Univariate | Multivariate | |||
---|---|---|---|---|
Variables | HR (95% CI) | p Value* | HR (95% CI) | p Value* |
Age | ||||
(< 70 years vs. ≥70 years) | 2.307 (0.93–5.76) | 0.073 | ||
Sex | ||||
(Male vs. Female) | 1.773 (1.20–2.61) | 0.004 | 1.679 (1.13–2.50) | 0.011 |
Prior nephrectomy | ||||
(yes vs. no) | 1.190 (0.41–3.46) | 0.749 | ||
ECOG PS | ||||
(0 vs. ≥1) | 2.481 (1.14–5.38) | 0.021 | ||
Treatment line of nivolumab | ||||
(2 vs. ≥3) | 1.371 (0.62–3.03) | 0.434 | ||
IMDC risk classification | ||||
(Favorable, Intermediate vs. Poor) | 1.939 (0.73–5.16) | 0.185 | ||
Number of Metastatic Organ site | ||||
(1,2 vs. ≥3) | 1.799 (0.83–3.89) | 0.135 | ||
CRP at baseline | ||||
(< 10 mg/L vs. ≥10 mg/L) | 1.025 (0.47–2.23) | 0.951 | ||
NLR at baseline | ||||
(< 3 vs. ≥3) | 1.011 (0.46–2.23) | 0.979 | ||
NLR at 4 weeks | ||||
(< 3 vs. ≥3) | 2.857 (1.14–7.18) | 0.026 | 2.734 (1.08–6.92) | 0.034 |